Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition. Last month, the European Medicines ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

The plaintiff, a Maryland man, claims he developed non-arteritic anterior ischemic optic neuropathy after taking Ozempic for diabetes.

At the 2-year, 3-year, and 4-year time points from the index date, those taking semaglutide had an increased risk for nonarteritic anterior ischemic optic neuropathy. HealthDay News — For patients ...